

Office use only

Category B form Special Access Scheme

Do not provide the name of the patient. Only provide the patient's initials and other information as requested on this form. Email completed form to SAS@tga.gov.au (preferred) or fax to (02) 6232 8112.

Privacy information

- For general privacy information, go to <http://www.tga.gov.au/about/website-privacy.htm>.
- The TGA is collecting personal information in this form in order to:
 - Assess the application.
 - Contact the medical practitioner and discuss the application where necessary.
- The personal information of the medical practitioner may be disclosed to State and Territory authorities with responsibility for therapeutic
 goods or medical practitioner registration.

PLEASE COMPLETE IN FULL AND CLEARLY – FORMS WILL NOT BE PROCESSED IF INCOMPLETE Patient details

Diagnosis	Citrullinaemia (Argininosuccinate Synthase Deficiency)		evious SAS No. (if applicable)	
Clinical justification for use of product				
Include seriousness of condition, details of previous treatment (attach additional pages if necessary)	Sodium phenylbutyrate is an ammonia sca binds with glutamine to from sodium phen combination with arginine and sodium ber	ylacetylglutamine ar	lised to sodium p d is excreted in t	phenylacetate, which the urine. This is use
N 1678				
24 1/27 5/24	Attach efficacy and safety data to support promote monitoring. **Must be completed for device		product and deta	ils of intended
24 (878) 5323			e/ Ambutyrate	
Product details	monitoring. **Must be completed for device	es. Trade nam	e/ Ambutyrate	
Product details Active ingredient*	monitoring. **Must be completed for device Sodium Phenylbutyrate 100g powder	es. Trade nam	Ambutyrate	
Product details Active ingredient* Company/supplier**	monitoring. **Must be completed for device Sodium Phenylbutyrate 100g powder Medsurge Healthcare	es. Trade nam device name	Ambutyrate of po Indefinite	

Prescriber details